SPH Sales revenues of Sopharma AD for March 2024
Sofia, Bulgaria, April 22, 2024 – According to the requirements of art. 100t of the Law on Public Offering of Sequrities (LPOS), “Sopharma” AD (SFA: “Bulgarian Stock Exchange” AD, SPH: Warsaw Stock Exchange) notifies that for March 2024 the Company recorded a decrease in sales of 24% compared to the same month of the previous year, incl. 8% decrease in domestic sales and 32% decrease in export sales, mainly due to destabilizing market dynamics on the main export destinations.
| Data | Tytuł | Kurs | Zmiana |
|---|
2024-05-30 | SPH Consolidated financial report according to IFRS as at 31 March 2024 | 13,30 | 0,00 |
2024-05-27 | SPH Invitation and Materials for Annual General Meeting of Shareholders of Sopharma AD | 13,05 | +1,15 |
2024-05-21 | SPH Sales revenues for April 2024 | 13,05 | 0,00 |
2024-04-30 | SPH Individual financial report according to IFRS as at 31 March 2024 | 13,05 | 0,00 |
2024-04-25 | SPH Publication of Annual consolidated audited financial report of "Sopharma" AD for 2023 in ESF format | 13,05 | 0,00 |
2024-04-22 | SPH Sales revenues of Sopharma AD for March 2024 | 13,70 | 0,00 |
2024-04-01 | SPH Presentation of the Annual Audited Individual Financial Statements of “Sopharma” AD as at 31 December 2022 | 13,40 | 0,00 |
2024-03-20 | SPH Sales revenues for February 2024 | 14,40 | -3,13 |
2024-03-12 | SPH Incoming transfer from capital increase subject to exercise of warrants from issue BG9200001212 | 14,00 | -1,43 |
2024-03-11 | SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 08 March 2024 on the acquisition of shares from a capital increase | 13,80 | +1,45 |
